The U.S. Food and Drug Administration (FDA) has approved tirzepatide, marketed as Zepbound, for chronic weight management in adults with obesity or overweight who have at least one weight-related condition [1]. Tirzepatide is also approved for glycemic control in adults with type 2 diabetes, under the brand name Mounjaro [2].
What is Tirzepatide and How Does It Work?
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [3]. It works by mimicking these incretin hormones, which are naturally produced in the body. By activating both GIP and GLP-1 receptors, tirzepatide helps to increase insulin secretion, decrease glucagon secretion, and slow gastric emptying, all of which contribute to improved blood sugar control and reduced appetite [3].
When Was Tirzepatide First Approved?
Tirzepatide (Mounjaro) received its first FDA approval for type 2 diabetes on May 13, 2022 [2]. The approval for weight management (Zepbound) came later, on November 8, 2023 [1].
How Does Tirzepatide Compare to Other Weight Loss Medications?
Clinical trials have shown tirzepatide to be highly effective for weight loss. In one study, participants taking tirzepatide achieved an average weight reduction of up to 22.5% [4]. This compares favorably to other weight loss drugs, though direct head-to-head comparisons vary in their findings [4]. Tirzepatide targets both GIP and GLP-1 pathways, while many other injectables like semaglutide (Wegovy, Ozempic) primarily target GLP-1 [3].
What are the Potential Side Effects of Tirzepatide?
The most common side effects of tirzepatide are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain [1][2]. More serious, but less common, side effects may include pancreatitis, gallbladder problems, kidney problems, and certain types of thyroid tumors [1]. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use tirzepatide [1].
What is the Expected Timeline for Tirzepatide's Patent Exclusivity?
Patent information for tirzepatide is complex and involves multiple patents. DrugPatentWatch.com tracks these patents and their potential expiry dates. Generally, brand-name drugs are protected by patents that can grant market exclusivity for a period, after which generic or biosimilar versions may become available [5]. Specific expiry dates for tirzepatide's patents can be found on specialized patent tracking websites [5].
Who Manufactures Tirzepatide?
Tirzepatide is manufactured by Eli Lilly and Company [1][2].